186 related articles for article (PubMed ID: 28495592)
21. Functional molecules in mesothelial-to-mesenchymal transition revealed by transcriptome analyses.
Namvar S; Woolf AS; Zeef LA; Wilm T; Wilm B; Herrick SE
J Pathol; 2018 Aug; 245(4):491-501. PubMed ID: 29774544
[TBL] [Abstract][Full Text] [Related]
22. Icodextrin: a review of its use in peritoneal dialysis.
Frampton JE; Plosker GL
Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
[TBL] [Abstract][Full Text] [Related]
23. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid.
Lin A; Qian J; Li X; Yu X; Liu W; Sun Y; Chen N; Mei C;
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1799-804. PubMed ID: 19808224
[TBL] [Abstract][Full Text] [Related]
24. Update on mechanisms of ultrafiltration failure.
Kim YL
Perit Dial Int; 2009 Feb; 29 Suppl 2():S123-7. PubMed ID: 19270200
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis.
Si M; Wang Q; Li Y; Lin H; Luo D; Zhao W; Dou X; Liu J; Zhang H; Huang Y; Lou T; Hu Z; Peng H
Sci Transl Med; 2019 Jun; 11(495):. PubMed ID: 31167927
[TBL] [Abstract][Full Text] [Related]
26. Icodextrin decreases technique failure and improves patient survival in peritoneal dialysis patients.
Wang IK; Li YF; Chen JH; Liang CC; Liu YL; Lin HH; Chang CT; Tsai WC; Yen TH; Huang CC
Nephrology (Carlton); 2015 Mar; 20(3):161-7. PubMed ID: 25487756
[TBL] [Abstract][Full Text] [Related]
27. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
Krediet RT
Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
[TBL] [Abstract][Full Text] [Related]
28. Glucose-based PD solution, but not icodextrin-based PD solution, induces plasminogen activator inhibitor-1 and tissue-type plasminogen activator in human peritoneal mesothelial cells via ERK1/2.
Katsutani M; Ito T; Masaki T; Kohno N; Yorioka N
Ther Apher Dial; 2007 Apr; 11(2):94-100. PubMed ID: 17381529
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Biocompatibility of Neutral Icodextrin Peritoneal Dialysis Fluid.
Shimada S; Mori T; Koizumi K; Sato S; Oba-Yabana I; Ohsaki Y; Sato E; Naganuma E; Kurasawa N; Tsuchikawa M; Ito S
Adv Perit Dial; 2016; 32():46-50. PubMed ID: 28988589
[TBL] [Abstract][Full Text] [Related]
30. The expression profiling and ontology analysis of noncoding RNAs in peritoneal fibrosis induced by peritoneal dialysis fluid.
Liu Y; Guo R; Hao G; Xiao J; Bao Y; Zhou J; Chen Q; Wei X
Gene; 2015 Jun; 564(2):210-9. PubMed ID: 25827714
[TBL] [Abstract][Full Text] [Related]
31. Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure.
López-Cabrera M; Aguilera A; Aroeira LS; Ramírez-Huesca M; Pérez-Lozano ML; Jiménez-Heffernan JA; Bajo MA; del Peso G; Sánchez-Tomero JA; Selgas R
Perit Dial Int; 2006; 26(1):26-34. PubMed ID: 16538870
[TBL] [Abstract][Full Text] [Related]
32. Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.
Yoon HE; Chang YK; Shin SJ; Choi BS; Kim BS; Park CW; Song HC; Yoon SA; Jin DC; Kim YS
J Korean Med Sci; 2014 Sep; 29(9):1217-25. PubMed ID: 25246739
[TBL] [Abstract][Full Text] [Related]
33. Periostin: a matricellular protein involved in peritoneal injury during peritoneal dialysis.
Braun N; Sen K; Alscher MD; Fritz P; Kimmel M; Morelle J; Goffin E; Jörres A; Wüthrich RP; Cohen CD; Segerer S
Perit Dial Int; 2013; 33(5):515-28. PubMed ID: 23378472
[TBL] [Abstract][Full Text] [Related]
34. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
35. WNT signaling is required for peritoneal membrane angiogenesis.
Padwal M; Cheng G; Liu L; Boivin F; Gangji AS; Brimble KS; Bridgewater D; Margetts PJ
Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1036-F1045. PubMed ID: 29363326
[TBL] [Abstract][Full Text] [Related]
36. Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients.
Zarrinkalam KH; Stanley JM; Gray J; Oliver N; Faull RJ
Kidney Int; 2003 Jul; 64(1):331-8. PubMed ID: 12787426
[TBL] [Abstract][Full Text] [Related]
37. MiR-200a ameliorates peritoneal fibrosis and functional deterioration in a rat model of peritoneal dialysis.
Wei X; Bao Y; Zhan X; Zhang L; Hao G; Zhou J; Chen Q
Int Urol Nephrol; 2019 May; 51(5):889-896. PubMed ID: 30888602
[TBL] [Abstract][Full Text] [Related]
38. A microrna screen to identify regulators of peritoneal fibrosis in a rat model of peritoneal dialysis.
Lin F; Wu X; Zhang H; You X; Zhang Z; Shao R; Huang C
BMC Nephrol; 2015 Apr; 16():48. PubMed ID: 25884636
[TBL] [Abstract][Full Text] [Related]
39. LncRNA RPL29P2 promotes peritoneal fibrosis and impairs peritoneal transport function via miR-1184 in peritoneal dialysis.
Li H; Zhang Y; Che M; Wang H; Li S; He P; Sun S; Xu G; Huang C; Liu X; Bai M; Zhou M; Su B; Zhang P; He L
Int J Med Sci; 2024; 21(6):1049-1063. PubMed ID: 38774747
[TBL] [Abstract][Full Text] [Related]
40. TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.
Kariya T; Nishimura H; Mizuno M; Suzuki Y; Matsukawa Y; Sakata F; Maruyama S; Takei Y; Ito Y
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F167-F180. PubMed ID: 28978530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
